Extended Data Fig. 1: Longitudinal volumetric changes in perilesional edema.
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
a, changes in perilesional FLAIR signal hyperintensity at each study MRI time point for individual patients. Patients are colored according to their mRANO responses. b, changes in perilesional FLAIR signal hyperintensity at each study MRI time point relative to baseline MRI. Data presented are mean +/− 95%CI. Patients are stratified by whether they developed clinically relevant edema requiring medical treatment. n = 9 independent patients developing edema requiring medical treatmet. * denotes statistical significance by two tailed unpaired t-test, 36 weeks P = 0.004 and 44 weeks P = 0.02.
